Research suggests SARS-CoV-2 vaccine distribution strategy focusing on where virus spreads more easily

NewsGuard 100/100 Score

The United States is a few days from reaching President Biden's goal of vaccinating 100 million people 100 days since he took office. While the United States leads the world in both the number of COVID-19 cases at over 29.7 million and deaths reaching past 539,000, it has stepped up as a leader in vaccinating its population.

However, the current vaccination strategy does not consider the basic reproduction number (R0), which helps to estimate the spread of COVID-19 cases.

A new preprint research paper published on the medRxiv* server by Anthony R. Ives from the University of Wisconsin-Madison and Claudio Bozzuto from the Wildlife Analysis GmbH suggests current vaccination efforts will have the United States reach herd immunity in about 4.5 months. However, they argue a more cost-effective and more effective vaccine strategy that takes geography into account. This would help allocate vaccines for high population counties that tend to be lower-class and with a high minority population. These counties are presently on track to be the last ones to reach herd immunity under the current vaccine distribution strategy.

The authors write:

"From an epidemiological perspective, because differences in R0 values among counties are partly driven by their population density, counties with the highest risk of resurgent and severe outbreaks are last at reaching herd immunity. From a socio-economic perspective, these high-density counties include many of those that are economic engines in the USA. Finally, high-density counties have relatively large African American populations, and the current distribution plan leads to a lag of about 4 days behind whites in reaching herd immunity."

Proposed vaccination strategy targets counties with high R0 numbers

Given that urban environments are at high risk of spreading the virus, dense populations produce a higher estimate of R0. Therefore, the authors argue that vaccination strategies should target dense populations to reach herd immunity sooner and avoid more COVID-19 cases.

To calculate this, they tracked the proportion of U.S. populations that would reach herd immunity under the current distribution strategy. Starting from March 15, 2021, they assume the following: the current vaccination rate using either of the three FDA approved vaccines — Moderna, Pfizer-BioNTech, or Johnson & Johnson — would be 1.58 million doses per day when 71.1 million people are already vaccinated with at least one dose, vaccines are 90% effective, and people who are vaccinated cannot spread COVID-19.

Their results showed herd immunity in the United States could be reached in approximately 130 days.

A feasible and efficient allocation of SARS-Cov-2 vaccines according to R0. Panel (a) shows the proportion of the US population living in counties having reached herd immunity, computed as 1 – 1/R0 at the county level; day 0 on the x-axis is March 15, 2021. The black line assumes the current distribution in which vaccines are sent evenly to counties according to population size, and the red line assumes the distribution depends on estimated county-level R0 values. Panel (b) shows the average population density of counties (individuals per km2) that reach herd immunity in a weekly time window. Panel (c) gives the proportions of white and African American communities living in counties that have achieved herd immunity.
A feasible and efficient allocation of SARS-Cov-2 vaccines according to R0. Panel (a) shows the proportion of the US population living in counties having reached herd immunity, computed as 1 – 1/R0 at the county level; day 0 on the x-axis is March 15, 2021. The black line assumes the current distribution in which vaccines are sent evenly to counties according to population size, and the red line assumes the distribution depends on estimated county-level R0 values. Panel (b) shows the average population density of counties (individuals per km2) that reach herd immunity in a weekly time window. Panel (c) gives the proportions of white and African American communities living in counties that have achieved herd immunity.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

New plan reaches herd immunity sooner in all counties

In contrast, their analysis suggests their proposed strategy would help the United States reach herd immunity around the same for all counties and 51 days sooner than the current vaccination strategy. In addition, the United States would ultimately use 39% fewer vaccines under the new plan.

"These results are contingent on the R0-based strategy starting mid-March; the overall benefits will expectedly shrink the longer the population size-based strategy is kept."

With new variants of concern from the United Kingdom, South Africa, and Brazil, the researchers note these estimates could change, and more vaccinations may be needed.

To account for the new variants' higher transmission rates, they adjusted their mathematical formula to include transmission 1.5 times higher than what was initially measured at the start of the pandemic in 2020.

The findings show that with the researchers' proposed strategy, the United States would reduce the time to reach herd immunity by 76 days and use up less than 35% of their vaccine doses.  

The evidence confirms that increasing vaccination efforts in more populated counties would be fairer and more efficient, use up fewer vaccines in the long-run, and reach herd immunity faster.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Jocelyn Solis-Moreira

Written by

Jocelyn Solis-Moreira

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Solis-Moreira, Jocelyn. (2021, March 21). Research suggests SARS-CoV-2 vaccine distribution strategy focusing on where virus spreads more easily. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20210321/Research-suggests-SARS-CoV-2-vaccine-distribution-strategy-focusing-on-where-virus-spreads-more-easily.aspx.

  • MLA

    Solis-Moreira, Jocelyn. "Research suggests SARS-CoV-2 vaccine distribution strategy focusing on where virus spreads more easily". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20210321/Research-suggests-SARS-CoV-2-vaccine-distribution-strategy-focusing-on-where-virus-spreads-more-easily.aspx>.

  • Chicago

    Solis-Moreira, Jocelyn. "Research suggests SARS-CoV-2 vaccine distribution strategy focusing on where virus spreads more easily". News-Medical. https://www.news-medical.net/news/20210321/Research-suggests-SARS-CoV-2-vaccine-distribution-strategy-focusing-on-where-virus-spreads-more-easily.aspx. (accessed April 24, 2024).

  • Harvard

    Solis-Moreira, Jocelyn. 2021. Research suggests SARS-CoV-2 vaccine distribution strategy focusing on where virus spreads more easily. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20210321/Research-suggests-SARS-CoV-2-vaccine-distribution-strategy-focusing-on-where-virus-spreads-more-easily.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Oregon study finds no clear link between mRNA vaccines and sudden cardiac deaths in young people